BioSpace News Archive

Fact.MR, a Market Research and Competitive Intelligence Provider - As per industry analysis on vancomycin by Fact.MR, a market research and competitive intelligence provider, the global market is predicted to expand at a CAGR of 5.8% over the forecast period and reach US$ 465.1 Million by 2027.

Wilmington, Delaware, United States: The global super-resolution microscopes market is expected to witness moderate growth during the forecast period between 2021 and 2031.

Wilmington, Delaware, United States: The global positron emission tomography market is expected to witness slow growth during the forecast period between 2021 and 2031.

Sweden-based NorthX Biologics is expanding into cell therapy manufacturing at its existing GMP-facility, as well as in premises at the Karolinska University Hospital campus in Stockholm.

The Cystic Fibrosis Foundation announced its investment of $6 million in Carbon Biosciences to support the company‘s preclinical research into an innovative gene therapy approach for cystic fibrosis.

Athersys, Inc. announced the Company’s slate of director candidates for its 2022 Annual Meeting of Stockholders being held on Thursday, July 28, 2022, at 8:30 a.m. ET.

Emergent BioSolutions Inc. announced that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle vaccine candidate were published in The Lancet Infectious Diseases.

Gelesis announced that Ro, a leading and rapidly growing U.S. direct-to-patient healthcare company, has placed a $15 million pre-paid order for the company’s commercial product for weight management, Plenity®.

ADMA Biologics, Inc. announced that the Company will be added to the Russell 2000® Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022.

Merck, known as MSD outside the United States and Canada, announced the presentation of positive results from the Phase 1/2 study, V116-001, evaluating the safety, tolerability and immunogenicity of V116, the company’s investigational 21-valent pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve adults 18-49 years of age and 50 years of age and older.